Among these, liraglutide in the LEADER study, semaglutide in the SUSTAIN-6, albiglutide in the Harmony Outcomes, dulaglutide in the REWIND, and efpeglenatide in the AMPLITUDE-O exhibited significant beneficial effects on 3-point major adverse cardiac events (3P-MACE: death from CV disease, non-fatal myocardial infarction, and non-fatal stroke), the primary end point of each study, compared to the placebo group, respectively
Something everyone who runs a monitoring program for people in early recovery needs to know
Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis
If you are not satisfied with a product or need advice, we are always at your disposal
Carlos-Bregni R, Contreras E, Netto AC, Mosqueda-Taylor A, Vargas PA, Jorge J, et al
Bc 3: V trng, st khun